Codexis (CDXS) Cash from Investing Activities (2010 - 2026)
Codexis (CDXS) recorded quarterly Cash from Investing Activities of -$1.1 million in Q1 2026, down 119.45% quarter-over-quarter from $5.7 million in Q4 2025, and down 109.44% on a YoY basis from $11.8 million in Q1 2025.
Codexis (CDXS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Codexis' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 109.44% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at $10.6 million (up 163.8% YoY), while the FY2025 annual figure was $23.5 million, up 141.25% from the prior year.
- Cash from Investing Activities was -$1.1 million for Q1 2026 at Codexis, down from $5.7 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $11.8 million in Q1 2025 to a low of -$28.6 million in Q1 2024.
- Historically, Cash from Investing Activities has averaged -$3.1 million across 5 years, with a median of -$1.1 million in 2026.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 3245.45% in 2023, then slumped 1624.19% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at $33000.0 in 2022, then soared by 3245.45% to $1.1 million in 2023, then slumped by 359.33% to -$2.9 million in 2024, then soared by 299.55% to $5.7 million in 2025, then plunged by 119.45% to -$1.1 million in 2026.
- The last three Cash from Investing Activities figures came in at -$1.1 million (Q1 2026), $5.7 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Codexis | 226.01 Mn | 160.87 Mn | 13.18 Mn | -1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.11 Mn |
| Mar 31, 2026 | -1.11 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Jun 30, 2025 | -367,000.00 |
| Jun 30, 2025 | -367,000.00 |
| Mar 31, 2025 | 11.77 Mn |
| Mar 31, 2025 | 11.77 Mn |
| Dec 31, 2024 | -2.86 Mn |
| Dec 31, 2024 | -2.86 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | -27.09 Mn |
| Jun 30, 2024 | -27.09 Mn |
| Mar 31, 2024 | -28.56 Mn |
| Mar 31, 2024 | -28.56 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Dec 31, 2023 | 1.10 Mn |